相关实验视频
Updated: Jul 10, 2025
05:50
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
1.2K
在骨关节炎中发生的突关节炎. 一个可治疗的目标?
1Departments of Rheumatology and Clinical Epidemiology, Leiden University Medical Centre, Postbox 9600, Leiden 2300RC, the Netherlands.
Seminars in arthritis and rheumatism
|November 26, 2023
概括
抗炎药物在针对特定细胞因子的骨关节炎试验中表现出有限的成功. 需要进一步的研究来了解炎症性关节炎,并确定有效的治疗方法来缓解长期的疼痛.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 膜炎症是骨关节炎 (OA) 的一个关键特征,与疼痛和关节损伤有关.
- 针对IL-1和TNFα等促炎细胞因子,在短期缓解疼痛的OA临床试验中产生了令人失望的结果.
- 皮质类固醇显示在OA中减轻疼痛,这表明其他炎症途径是相关的.
研究的目的:
- 探索抗炎药物在骨关节炎中有效性有限的原因.
- 为了研究由突炎驱动的骨关节炎和组织间交叉声调的病理生物学.
- 为未来的临床试验确定合适的患者群体和结果措施.
主要方法:
- 对九项随机临床试验的综述,这些试验针对骨关节炎中的促炎细胞因子 (IL-1,TNFα).
- 分析目前对膜炎病理生物学和OA组织杂交的理解.
- 考虑临床试验设计,包括后续持续时间和结果措施.
主要成果:
- 针对IL-1和TNFα的9项试验未能在骨关节炎中显示出显著的短期疼痛缓解.
- 缺乏对膜炎驱动的内型和组织交叉语音的洞察力,使患者的选择和结果测量变得复杂.
- 现有的炎症性OA的分类标准对于患者的选择是不够的.
结论:
- 某些抗炎药物的无效可能源于针对错误的介质或患者群体.
- 需要进一步的研究来了解炎症性关节炎的多样性病理生物学.
- 未来的试验应该包括更长的随访期 (至少一年),以评估疾病的改变和持续的疼痛缓解.
相关概念视频
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
01:38Inflammation
53.6K
Overview
53.6K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
01:24T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121